Serzone Settlement Pending: Bristol Would Pay “At Least” $70 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb is offering to pay "at least" $70 mil. to resolve product liability claims related to the antidepressant Serzone (nefazodone) under a proposed settlement awaiting approval in West Virginia federal court
You may also be interested in...
Bristol Pulls Serzone; Cites Generic Erosion, Not Safety Issues
In a letter to wholesalers, Bristol said the antidepressant will no longer be shipped after June 14. Public Citizen called the withdrawal inadequate since the company is not ordering a recall and nefazodone generics are still available.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.